Jpmorgan Chase & CO Compugen LTD Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Compugen LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 67,485 shares of CGEN stock, worth $101,902. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,485
Previous 180,772
62.67%
Holding current value
$101,902
Previous $303,000
59.74%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CGEN
# of Institutions
73Shares Held
13.1MCall Options Held
79.2KPut Options Held
12.7K-
Silverarc Capital Management, LLC1.5MShares$2.27 Million0.68% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.29MShares$1.94 Million0.0% of portfolio
-
Taylor Frigon Capital Management LLC1.2MShares$1.81 Million1.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl1.09MShares$1.65 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C31.02MShares$1.54 Million0.0% of portfolio
About COMPUGEN LTD
- Ticker CGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 86,624,600
- Market Cap $131M
- Description
- Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...